A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Interventionnel
Phase 3
Sun Yat-sen University Cancer Center
Sponsor: Shandong Suncadia Medicine
Dernière synchronisation : 26 janvier 2026 Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.
Catégorie de traitement
Autres médicaments, Hormonothérapie, Thérapie ciblée
1. Women aged 18 to 75 years old (including both values).
2. ECOG Physical Strength Status (PS) : 0 to 1 point.
3. Patients with locally advanced or metastatic breast cancer confirmed by histology.
4. Patients previously received 1-2 lines of endocrine therapy.
5. Expected survival > 6 months.
6. The functional level of the organs must meet the requirements.
7. Subjects that voluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent.
Critères d'exclusion
1. Patients with rapid disease progress and investigators determine that endocrine therapy is not suitable or tolerant.
2. A history of severe clinical cardiovascular diseases.
3. Patients with uncontrollable tumor-related pain as judged by investigators.
4. Severe infection exists within 4 weeks before the first study administration.
5. Patients with clinically significant endometrial abnormalities.
6. Untreated active hepatitis.
7. Patients known to be allergic to HRS-8080 components.
8. Pregnant and lactating women, or those planning to become pregnant during the study period.
Pensez-vous que cet essai apparaît incorrectement ?
Détails de la conception
AllocationRandomized
Modèle d'interventionParallel Assignment
MasquageNone (Open Label)
Nombre à inscrire240
Bras et interventions
Bras
Interventions
Type : Experimental
Description :
Interventions :
HRS-8080 Tablet
Fulvestrant injection
Exemestane tablets
Everolimus Tablets
Anastrozole Tablets
Letrozole Tablets
Mesures des résultats
Mesures des résultats primaires
Progression free survival (PFS) evaluated by the blinded independent central review (BICR).Approximately 2 years.
Mesures des résultats secondaires
Overall response rate (ORR).Approximately 2 years.
Clinical benefit rate (CBR).Approximately 2 years.
Duration of response (DOR).Approximately 2 years.
Overall survival (OS).Approximately 3 years.
Adverse events (AEs).Approximately 2 years.
Serious adverse events (SAEs).Approximately 2 years.
Progression free survival (PFS) evaluated by investigators.Approximately 2 years.
Mettre l'essai en favori
Partager l'essai
Télécharger l'essai
Pensez-vous que cet essai apparaît incorrectement ?